<DOC>
	<DOCNO>NCT01675245</DOCNO>
	<brief_summary>The purpose study acquire information usage , effectiveness , safety , level health care resource utilization associate Velcade therapy recurrent refractory multiple myeloma patient initiate Velcade various combination therapy within approve indication naturalistic setting .</brief_summary>
	<brief_title>An Observational Study Chinese Multiple Myeloma Patients Treated With Velcade</brief_title>
	<detailed_description>This national , multi-center ( study conduct multiple site ) , non-interventional ( scientific study one investigator monitor one patient treated medication ) , observational study ( scientific study make clear easy understanding cause effect relationship ) Chinese Multiple Myeloma patient treat Velcade . The study consist 3 phase , include , screen phase , treatment phase , follow phase . In screen phase , data collect basis patient 's demographic status , component disease severity assessment , potential prognostic factor . Data prior cancer treatment collect retrospectively baseline patient receive cancer treatment prior receive Velcade . In treatment phase , Velcade administer intravenously 2-week treatment period follow 10-day rest period . Each treatment cycle consist 21 day . Prospective ( participant first identify follow forward time pass ) observational data collect treatment Velcade . In follow phase , patient follow three year document long-term survival data . For patient reinitiate Velcade , data collection follow Velcade treatment period documentation process . Safety evaluation base incidence , intensity , type adverse event . The total duration study set prospectively three year date patient ' initiation Velcade .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Must give informed consent agreement local legislation Must contraindication list package insert Patients currently participate another investigational study Velcade medication Patients severe hepatic renal impairment Patients platelet count 25000/Î¼l Patients consider disqualified study investigator</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Cancer</keyword>
	<keyword>Velcade</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Chinese patient</keyword>
</DOC>